feed,title,long_url,short_url
Benzinga,"After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer",https://benzinga.com/general/biotech/23/05/32590040/after-back-to-back-failure-for-keytruda-plus-lenvima-merck-touts-durable-clinical-benefit-for-the,https://da.gd/oXHBQv
